Tests a food supplement against placebo in women with endometriosis and pelvic pain
Tests the Doliral food supplement in adult women with endometriosis and pelvic pain.
Plain-language title generated from the registry record
Registry title: Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Arafarma Group, S.A.
- Trial code
- NCT07393958
- Record updated
- 30 October 2026
- Original description
This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.Read full original descriptionShow less
Experimental Study of Quality of Life in Patients With Endometriosis and Pelvic Pain Treated With Doliral Dietary Supplementation Versus Placebo.
This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.
Inclusion: Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification; Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound; Presence of pelvic pain (VAS > 4) during the last three months; No indication for surgical intervention at the time of inclusion in the study; Patients who are able to provide informed consent.
Exclusion: Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study; Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study; Patients with known allergy or hypersensitivity to Doliral®; Patients under 18 years of age; Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day; Pregnant or breastfeeding patients; Patients on sick leave: > 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.